Literature DB >> 16917947

Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.

A L E Montalvo1, B Bembi, M Donnarumma, M Filocamo, G Parenti, M Rossi, L Merlini, E Buratti, P De Filippi, A Dardis, M Stroppiano, G Ciana, M G Pittis.   

Abstract

Glycogen storage disease type II (GSDII) is a recessively inherited disorder due to the deficiency of acid alpha-glucosidase (GAA) that results in impaired glycogen degradation and its accumulation in the lysosomes. We report here the complete molecular analysis of the GAA gene performed on 40 Italian patients with late onset GSDII. Twelve novel alleles have been identified: missense mutations were functionally characterized by enzyme activity and protein processing in a human GAA-deficient cell line while splicing mutations were studied by RT-PCR and in silico analysis. A complex allele was also identified carrying three different alterations in cis. The c.-32-13T > G was the most frequent mutation, present as compound heterozygote in 85% of the patients (allele frequency 42.3%), as described in other late onset GSDII Caucasian populations. Interestingly, the c.-32-13T > G was associated with the c.2237G > A (p.W746X) in nine of the 40 patients. Genotype-phenotype correlations are discussed with particular emphasis on the subgroup carrying the c.-32-13T > G/c.2237G > A genotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917947     DOI: 10.1002/humu.20374

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  42 in total

1.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

2.  Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.

Authors:  Paula Hernández-Arévalo; José D Santotoribio; Rocío Delarosa-Rodríguez; Antonio González-Meneses; Salvador García-Morillo; Pilar Jiménez-Arriscado; Juan M Guerrero; Hada C Macher
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

3.  Molecular diagnosis of German patients with late-onset glycogen storage disease type II.

Authors:  P R Joshi; D Gläser; S Schmidt; M Vorgerd; M Winterholler; K Eger; S Zierz; M Deschauer
Journal:  J Inherit Metab Dis       Date:  2008-07-10       Impact factor: 4.982

Review 4.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

5.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

6.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

Review 7.  The missing puzzle piece: splicing mutations.

Authors:  Marzena A Lewandowska
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

8.  Late-onset Pompe disease: a genetic-radiological correlation on cerebral vascular anomalies.

Authors:  A Pichiecchio; S Sacco; P De Filippi; E Caverzasi; S Ravaglia; S Bastianello; C Danesino
Journal:  J Neurol       Date:  2017-08-30       Impact factor: 4.849

9.  Molecular genetics of late onset glycogen storage disease II in Italy.

Authors:  M G Pittis; M Filocamo
Journal:  Acta Myol       Date:  2007-07

10.  The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.

Authors:  Caterina Porto; Monica Cardone; Federica Fontana; Barbara Rossi; Maria Rosaria Tuzzi; Antonietta Tarallo; Maria Vittoria Barone; Generoso Andria; Giancarlo Parenti
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.